Palonosetron Fresenius Kabi (Palonosetron Hydrochloride)

Palonosetron Hydrochloride, the active ingredient in Palonosetron Fresenius Kabi, is a selective 5‑HT3 receptor antagonist presented as a sterile injectable solution for intravenous use. It is used to prevent chemotherapy‑induced nausea and vomiting in adult cancer patients.

GNH USA supplies Palonosetron Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Palonosetron Fresenius Kabi is a 5‑HT3 receptor antagonist indicated for several chemotherapy‑related indications.

- Chemotherapy‑induced nausea and vomiting (CINV): helps prevent both acute and delayed episodes in adult patients. - Post‑operative nausea and vomiting (PONV): reduces the incidence of nausea and vomiting after general anesthesia. - Radiotherapy‑induced nausea and vomiting: provides prophylaxis for patients receiving moderately emetogenic radiotherapy. - Antiemetic prophylaxis for highly emetogenic chemotherapy regimens: offers extended protection beyond the first 24 hours.

Palonosetron may cause adverse reactions, most of which are mild to moderate in intensity.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional, self‑limiting. - Fatigue: generally transient. - Diarrhoea: mild and short‑lived. - Dizziness: occasional, resolves without intervention. - Injection site erythema: mild redness at the site of administration.

Serious or Rare Side Effects: - Allergic reaction: rash, pruritus, or anaphylaxis. - QT prolongation: may affect cardiac rhythm in susceptible patients. - Serotonin syndrome: rare when combined with other serotonergic agents. - Severe constipation or bowel obstruction: requires medical evaluation. - Persistent hypotension: notable drop in blood pressure post‑administration. - Neuro‑muscular weakness: very rare, may indicate a severe hypersensitivity response.

When using Palonosetron Fresenius Kabi, clinicians should consider several safety aspects.

- Cardiac monitoring: patients with known QT‑interval prolongation should be observed. - Concomitant serotonergic drugs: assess risk of serotonin syndrome. - Electrolyte imbalance: correct hypokalaemia or hypomagnesemia before use. - Renal impairment: dose adjustment may be required in severe cases. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly justified. - Store at ambient temperature: keep in original packaging, protect from light and moisture.

Palonosetron can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - QT‑prolonging agents: concurrent use may increase risk of cardiac arrhythmias. - CYP3A4 inhibitors strong (e.g., ketoconazole): may raise palonosetron plasma levels.

Moderate Interactions (Monitor Closely): - Other antiemetics (e.g., dexamethasone, aprepitant): may require dose timing adjustments. - Serotonergic agents (e.g., SSRIs, SNRIs): monitor for signs of serotonin syndrome. - Diuretics: watch for electrolyte disturbances that could potentiate cardiac effects. - Antifungal azoles: may modestly increase exposure. - Opioids: observe for additive central nervous system depression.